Shares of Portola Pharmaceuticals Inc. (NASDAQ:PTLA) climbed 46.6 percent to close at $56.06 on Friday after the company won FDA approval for its once-daily factor Xa inhibitor, Bevyxxa (betrixaban), for the prevention of venous thromboembolism (VTE) in certain adults.